Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ).
Biocytogen Pharmaceuticals held its first extraordinary general meeting of 2025, where several key resolutions were approved by shareholders. The meeting, conducted both physically and virtually, saw the approval of the proposed issuance of A Shares and amendments to the company’s Articles of Association, reflecting strategic moves to enhance its market presence and operational framework.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a pharmaceutical company based in China, primarily focused on the development and commercialization of innovative drugs and therapeutic solutions. The company operates within the biopharmaceutical industry, targeting advancements in biotechnology and pharmaceutical research.
Average Trading Volume: 488,942
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.33B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.